1. Home
  2. PHAR

as 05-30-2025 4:00pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Founded: 1988 Country:
Netherlands
Netherlands
Employees: N/A City: N/A
Market Cap: 718.1M IPO Year: N/A
Target Price: $30.00 AVG Volume (30 days): 3.1K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.02 EPS Growth: N/A
52 Week Low/High: $6.65 - $11.07 Next Earning Date: 05-08-2025
Revenue: $320,708,000 Revenue Growth: 24.13%
Revenue Growth (this year): 13.31% Revenue Growth (next year): 7.68%

PHAR Daily Stock ML Predictions

Share on Social Networks: